Disease · HP_0100582
Nasal polyposis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Nasal polyposis. Diseases, record HP_0100582. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0100582
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Nasal polyposis
- Open Targets ID
- HP_0100582
- Other names
- Nasal polyps, Polyposis nasi, Polyps of nose
- Highest stage of its drugs
- Approval, for 4 of its 22 drugs, from DailyMed and EMA Human Drugs
Source Open Targets
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DUPILUMAB | CHEMBL2108675 | Antibody | Approval | DailyMed | 11 | 10 | 10 | Drugs and targets |
| FLUTICASONE PROPIONATE | CHEMBL1473 | Small molecule | Approval | DailyMed | 8 | 7 | 7 | Drugs and targets |
| MOMETASONE FUROATE | CHEMBL1161 | Small molecule | Approval | DailyMed | 3 | 1 | 1 | Drugs and targets |
| DEPEMOKIMAB | CHEMBL4650469 | Antibody | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BENRALIZUMAB | CHEMBL1742991 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CICLESONIDE | CHEMBL2040682 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FEVIPIPRANT | CHEMBL3137332 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIMEGEPANT | CHEMBL2178422 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MEPOLIZUMAB | CHEMBL2108429 | Antibody | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets19
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Approval | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IL5 | Interleukin-5 | 2 | Interleukin-5 inhibitor | Approval | https://conductscience.org/library/genes/3567 | Drugs and targets |
| ADRB1 | Beta-1 adrenergic receptor | 1 | Beta-1 adrenergic receptor antagonist | Phase 2 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ATP4A | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Unknown | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Unknown | https://conductscience.org/library/genes/496 | Drugs and targets |
| AVPR1A | Vasopressin receptor | 1 | Vasopressin receptor agonist | Phase 2 | https://conductscience.org/library/genes/552 | Drugs and targets |
| AVPR1B | Vasopressin receptor | 1 | Vasopressin receptor agonist | Phase 2 | https://conductscience.org/library/genes/553 | Drugs and targets |
| AVPR2 | Vasopressin receptor | 1 | Vasopressin receptor agonist | Phase 2 | https://conductscience.org/library/genes/554 | Drugs and targets |
| CALCRL | Calcitonin gene-related peptide type 1 receptor | 1 | Calcitonin gene-related peptide type 1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/10203 | Drugs and targets |
| IGHE | Immunoglobulin heavy constant epsilon | 1 | Ig epsilon chain C region inhibitor | Phase 2 | https://conductscience.org/library/genes/3497 | Drugs and targets |
1 to 10 of 19
See all 19 targetsTrials35
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01623323 | Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps | Phase 3 | 705 | 2016-03-01 | Chronic Sinusitis With or Without Nasal Polyps | FLUTICASONE PROPIONATE | Its record names the disease | ClinicalTrials.gov |
| NCT03170271 | A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. | Phase 3 | 660 | 2020-12-16 | Asthma | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02898454 | Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps | Phase 3 | 448 | 2019-10-23 | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | DUPILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01622569 | Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety | Phase 3 | 323 | 2018-12-05 | Bilateral Nasal Polyposis | FLUTICASONE PROPIONATE | Its record names the disease | ClinicalTrials.gov |
| NCT01624662 | Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device | Phase 3 | 323 | 2018-12-05 | Bilateral Nasal Polyposis | FLUTICASONE PROPIONATE | Its record names the disease | ClinicalTrials.gov |
| NCT04157335 | Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) | Phase 3 | 295 | 2026-02-19 | Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02912468 | A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps | Phase 3 | 276 | 2019-07-25 | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | DUPILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05248997 | Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis | Phase 3 | 261 | 2025-03-26 | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | RIMEGEPANT | Its record names the disease | ClinicalTrials.gov |
| NCT01362244 | Mepolizumab in Nasal Polyposis | Phase 2 | 109 | 2016-03-28 | Nasal Polyps | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03681093 | Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma | Phase 3 | 98 | 2021-01-05 | Nasal Polyps | FEVIPIPRANT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 35
See all 35 trialsComparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Benralizumab vs Placebo: Time to First Asthma Exacerbation (up to Week 24) | 123 of 427 | 107 of 229 | 656 | NCT03170271 | Trial comparisons |
| Benralizumab vs Placebo: deaths from any cause | 0 of 427 | 0 of 229 | 656 | NCT03170271 | Trial comparisons |
| Benralizumab vs Placebo: serious adverse events | 23 of 427 | 25 of 229 | 656 | NCT03170271 | Trial comparisons |
| Dupilumab 300 mg vs Placebo: deaths from any cause | 0 of 143 | 0 of 132 | 275 | NCT02912468 | Trial comparisons |
| Dupilumab 300 mg vs Placebo: serious adverse events | 6 of 143 | 19 of 132 | 275 | NCT02912468 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery and/or Use SCS for CRSwNP | 26 of 139 | 30 of 135 | 274 | NCT04157335 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery for CRSwNP | 8 of 139 | 10 of 135 | 274 | NCT04157335 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With SCS Use for CRSwNP | 21 of 139 | 22 of 135 | 274 | NCT04157335 | Trial comparisons |
| Rimegepant vs Placebo: deaths from any cause | 0 of 99 | 0 of 105 | 204 | NCT05248997 | Trial comparisons |
| Rimegepant vs Placebo: serious adverse events | 0 of 99 | 0 of 105 | 204 | NCT05248997 | Trial comparisons |
1 to 10 of 20
See all 20 comparisons in its trialsPapers from its trials52
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0100582
GET https://conductscience.org/api/diseases/v1/HP_0100582/drugs?page=2